アクセンチュア アクセンチュア株式会社 Official site

Long-term Listed Product Portfolio Restructuring Practical Framework

How to utilize and let go of products whose patents have expired. Progressing with continuity, consolidation, and transfer in a planned manner to generate resources for new drugs.

We provide a practical framework to support pharmaceutical companies in restructuring their portfolios based on evaluations of long-listed products and reviewing their production and supply systems. In response to the accelerating decline in sales due to the introduction of selected treatment cost systems and the expansion of generic drug shares, we simultaneously achieve fixed cost reductions and secure funding for new drugs. We are open to consultations regarding current diagnostics, so please feel free to contact us.

basic information

[Specifications] - Long-term listed product portfolio reorganization 4-layer framework (product evaluation, production system reorganization, transfer handover, management investment decision) - Reorganization execution roadmap (three steps: evaluation, planning, execution) - Comparison framework of conventional responses and desired outcomes - Long-term listed product reorganization self-diagnosis check - Current situation diagnosis (free consultation) provided

Price range

Delivery Time

Applications/Examples of results

【Uses and Examples of Achievements】 - Identification of reorganization priorities based on profitability understanding of long-listed products and sales decline forecasts - Development of portfolio strategies considering the annual revisions of the selected medical care fee system and drug prices - Planning for production consolidation, transfer, and outsourcing in response to the expansion of generic drug market share - Design of production transfer schedules incorporating approval procedures - Formulation of policies for the transfer of long-listed products to other companies and designing handover processes to maintain stable supply - Redistribution plan of funds generated from fixed cost reductions to new drug research and development

Reorganization of the portfolio of long-listed pharmaceuticals.

PRODUCT

Recommended products

Distributors

Accenture transforms change into power, providing 360-degree value to customers, employees, shareholders, partner companies, and society. We support Bristol Myers Squibb by leveraging generative AI and automation to accelerate clinical trials and streamline drug development. We consolidate our full capabilities as a reinvention service to solve the most challenging problems. We guide enterprise transformation to be executed on a larger scale and with greater impact.